The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | Early versus delayed initiation of ropeginterferon alfa-2b in high-risk ET in the SURPASS-ET trial
Ruben Mesa, MD, Levine Cancer Institute, Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston Salem, NC, discusses the two-year findings of the SURPASS-ET trial (NCT04285086), highlighting the impact of early versus delayed initiation of ropeginterferon alfa-2b in high-risk essential thrombocythemia (ET). Dr Mesa notes that the study’s findings suggest that earlier use of ropeginterferon may confer benefits and have a deeper impact on long-term outcomes, supporting its use earlier in the disease course. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
